Advanced Health Intelligence Ltd
Advanced Health Intelligence — Investor Presentation (January 2026)
20 slides from Advanced Health Intelligence's investor presentation, January 2026
Slide 1: Company presentation January 2026
Company presentation January 2026
Slide 2: Confidential – Important notice and disclaimer
Confidential – Do not duplicate or distribute without the written permission of Advanced Health Intelligence Ltd This presentation (“Presentation”) has been prepared by Advanced Health Intelligence Ltd (“Advanced Cooling off rights do not apply to the acquisition of Advanced Health Intelligence shar
Slide 3: AHI Partners with Dr. Obaid Alketbi and The Dr. O Group
AHI Partners with His Excellency Dr. Obaid Alketbi and The Dr. O Group to Transform Healthcare Across the Middle East We are proud to share AHI’s strategic partnership with His Excellency Dr. Obaid Alketbi and The Dr. O Group a collaboration that reflects a shared commitment to redefining healthcare
Slide 4: About AHI
About AHI AHI is leveraging digital technology to revolutionise Cardio Metabolic Remote Patient Management and Monitoring Empowering physicians, payers, patients and pharma to: • Increase access to remote non-invasive and simple to conduct assessment of digital biomarkers, vital signs and associated
Slide 5: Company trajectory: 10 years of science and development
Company trajectory AHI has dedicated 10 years of Science and Development with $100m invested aimed at Cardio Metabolic Disease 2014-19 2020-22 2023-25 2026 onward Product development, building our research and evidence base, growing our patent portfolio and Focus on commercialization market finding
Slide 6: AHI's Money Shot: obesity remote patient care platform
Company trajectory AHI’s Money Shot: starting with an obesity remote patient care platform with a personalized digital health coach, companion and physician advisor A digital-first, obesity cause-finding, learning and orchestration platform that journeys with the obesity patient and their primary ca
Slide 7: Where we are today
& ahi Where we are today
Slide 8: AHI Sensing and Data Stack offers patented remote digital biomarker solutions
Product development AHI Sensing and Data Stack offers patented remote digital Cardio Metabolic biomarker solutions primed for Obesity Digital Analyses 47 health markers and 35 health risks in <15 minutes, including obesity, diabetes, hypertension, cardiovascular disease, metabolic syndrome and menta
Slide 9: We have 25 issued patents; with 45 pending or published
Growing our patent portfolio We have 25 issued patents; with 45 pending or published KEY: # Issued (pending / published) # Pending / published 1 (3) 1 (8) 5 (2) 5 (3) (1) 1 (4) (1) 4 (4) (3) (3) Topics include: (4) • Imaging / analysing a body (3) 4 • Assessing disease risks from user captured data
Slide 10: Growing global partner base and ramping up revenue
Go-to-market We have a growing global partner base and will continue to ramp up Revenue whilst we commercialise the money shot AHI is projected to continue its growth trajectory, with target revenue from existing solutions estimated at >$25m by 2028 Customer validation stage Build in progress Soluti
Slide 11: Obesity Market opportunity
& ahi Obesity Market opportunity
Slide 12: Why obesity: $1 trillion global problem with high unmet needs
Obesity market Why obesity: $1 trillion global problem with high unmet needs, fast growth and future potential Current market Remaining unmet need / complications Expectations for future potential in addressing those • Growth market with global drug of spend • There are still >1bn people living with
Slide 13: Obesity is at the epi-centre of cardio metabolic disease
Obesity market Obesity is at the epi-centre for cardio metabolic disease leading to premature death Causes of obesity and its association with increased cardiovascular risk factors according to the American College of Cardiology Environmental and social determinants of health Neurologic and psycholo
Slide 14: Obesity will increasingly become a chronic disease
Future obesity landscape Obesity will increasingly become a chronic disease with active remote patient treatment approaches in large populations serviced by GLP1’s Perspective From To • Actively driving their own health through self advocacy • Driving their own care pathways with increasing influenc
Slide 15: ACC guidelines recommend a multidisciplinary approach including drugs
Future obesity landscape Guidelines from the American College of Cardiology recommend a multidisciplinary approach including drugs Multidisciplinary team approach for weight management Weight Loss Thresholds Associated With Comorbidity Improvements Doctors, • Improvement in triglycerides, blood nurs
Slide 16: Playbook – tapping into money flow unlocked by Big Pharma
Target markets Playbook – AHI will tap into the existing money flow being unlocked by Big Pharma – multiple sources of income to be exploited Stakeholder Deployment Payment model Potential fees Pharma Companion diagnostic or R&D tool Annual licence fee $millions annually Monthly program management f
Slide 17: Target markets include payer or provider segments in US, AsiaPac and UAE
Target markets Target markets include payer or provider segments in US, AsiaPac and UAE Industry targets Geographies Future potential Characteristic Health care / clinical Hospital based care coordination ✓ ✓ Initial High insured population ✓ ✓ target Need for efficiencies within high health care sp
Slide 18: Our leadership has 180+ years experience in relevant fields
Leadership Our leadership has 180+ years experience in relevant fields Board Nick Prosser, PeterGoldstein, Low Koon Low, Mike Melby, Jacqueline Yee, Chairman Independent Director Independent Director Independent Director Independent Director • 15+ years ICT experience. • 30 years capital market, M&A
Slide 19: Thank-you
Thank-you For more information on how Advanced Health Intelligence how our technologies can help you, email us at hello@ahi.tech, or find out more at https://ahi.tech “We didn’t create the science, we digitized it.” Vlado Bosanac , AHI Founder Locations: Asia Pacific: Australia, Singapore Email: vla
Slide 20: We will build out and scale the product as proof of value evolves
Product roadmap We will build out and scale the product as proof of value evolves Core principles Value-based success Patient-first access Ethical routing Our success is measured in time to right care and Patients do not pay out of pocket; access is funded We avoid pay-per-referral kickbacks; routin
Advanced Health Intelligence — Investor Presentation (January 2026) on 6ix